TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from LTR Pharma Limited ( (AU:LTP) ).
LTR Pharma Limited announced that clinical data from its Phase I study of SPONTAN, an intranasal vardenafil formulation for erectile dysfunction, has been published in the European Journal of Pharmaceutical Sciences. The study shows that SPONTAN achieves peak plasma concentrations significantly faster than oral tablets, offering a rapid onset of action that addresses the spontaneity challenge faced by many ED patients. This publication enhances LTR Pharma’s regulatory dossier, supporting its commercialization efforts in various markets and potentially transforming ED treatment by improving patient adherence and satisfaction.
More about LTR Pharma Limited
LTR Pharma Limited operates in the pharmaceutical industry, focusing on innovative drug delivery platforms. The company specializes in developing intranasal formulations for erectile dysfunction, with products like SPONTAN and ROXUS targeting the global ED market.
Average Trading Volume: 515,376
Technical Sentiment Signal: Sell
For an in-depth examination of LTP stock, go to TipRanks’ Overview page.